Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIqgeo Regulatory News (IQG)

Share Price Information for Iqgeo (IQG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 467.00
Bid: 462.00
Ask: 472.00
Change: 0.00 (0.00%)
Spread: 10.00 (2.165%)
Open: 467.00
High: 467.00
Low: 467.00
Prev. Close: 467.00
IQG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directors' Dealings

22 Jun 2017 10:51

RNS Number : 8776I
Ubisense Group PLC
22 June 2017
 

22 June 2017

 

Ubisense Group Plc

Directors' Dealings

Ubisense Group plc (LSE:UBI, "Company" or "Ubisense") received notification on 21 June 2017 from Kestrel Partners LLP ("Kestrel") that on 21 June 2017 it acquired, on behalf of its discretionary clients, 115,000 ordinary shares of 2p each ("Shares") in the Company at a price of £0.37 per share. The notification also included the matters set out below.

Kestrel is the investment manager to Kestrel Opportunities, a cell of Guernsey Portfolios PCC Limited ("Kestrel Opportunities"), and various other clients. This disclosure relates to indirect Shares and voting rights in the Company that are managed by Kestrel on a discretionary basis.

Mr Scott is a partner of, and holds a beneficial interest in Kestrel. Mr Scott is also a shareholder in Kestrel Opportunities and is therefore deemed to have a beneficial interest in Kestrel Opportunities' entire legal holding in Ubisense.

Prior to this purchase of Shares, Kestrel on a combined basis indirectly held Shares and voting rights over 15,915,493 Shares in the Company.

Of the Shares purchased, 97,750 were acquired on behalf of Kestrel Opportunities and following this transaction, Kestrel Opportunities holds (and consequently Mr Scott is deemed to have a beneficial interest in) 11,855,785 Shares in the Company. The remaining 17,250 Shares were purchased on behalf of Kestrel's other discretionary clients, in which Mr Scott has no beneficial interest, who, following this transaction, hold a further 4,174,708 Shares in the Company.

Following this transaction and on a combined basis, Kestrel indirectly holds voting rights over 16,030,493 Shares in the Company, which represents approximately 28.69% per cent of the Company's issued share capital.

Kestrel's interest in the Shares in the Company is held through the following nominees:

 

Holding type

Nominee

No. of shares

% of issued share capital

Indirect

Bank of New York Nominees Ltd

11,855,785

21.22%

Indirect

JIM Nominees Limited

1,306,095

2.34%

Indirect

Bank of New York Nominees Ltd

2,868,613

5.13%

 

For further information contact:

 

Ubisense Group PLCPeter Harverson

Tim Gingell

 

+44 (0) 1223 535 170

Numis Securities LimitedSimon Willis

Jamie Lillywhite

Toby Adcock

+44 (0) 20 7260 1000

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHKMGZVLZGGNZG
Date   Source Headline
23rd Mar 20217:00 amRNSFinal Results
2nd Mar 20217:00 amRNSInvestor Presentation
29th Jan 20217:00 amRNSContract Win
18th Jan 202111:10 amRNSDirector/PDMR Shareholding
18th Jan 20217:00 amRNSTrading Update
6th Jan 202110:57 amRNSDirector/PDMR Shareholding
31st Dec 202012:00 pmRNSBlock listing Interim Review
31st Dec 20207:00 amRNSDisposal of Minority Interest
22nd Dec 20205:14 pmRNSHolding(s) in Company
22nd Dec 20203:46 pmRNSHolding(s) in Company
22nd Dec 20207:00 amRNSContract Win
21st Dec 20208:30 amRNSCompletion of Fundraising, Acquisition & TVR
18th Dec 20205:15 pmRNSInitial Consideration Shares
18th Dec 202010:51 amRNSResult of General Meeting
8th Dec 20203:52 pmRNSHolding(s) in Company
3rd Dec 20207:00 amRNSGrant of Options
1st Dec 20202:50 pmRNSResults of Fundraising
1st Dec 20208:45 amRNSProposed Acquisition and Fundraising
28th Oct 20203:53 pmRNSChange of Registered Office
19th Oct 20207:00 amRNSIQGeo announces major contract extension
14th Sep 20207:00 amRNSInterim Results 1H 2020
7th Sep 20207:00 amRNSInvestor Presentation
3rd Sep 20207:00 amRNSIQGeo announces major new telecoms customer in USA
4th Aug 20207:00 amRNSDirectorate Change
20th Jul 20201:55 pmRNSDirectors' Dealings
14th Jul 20207:00 amRNSIQGeo Trading Update
2nd Jul 20207:00 amRNSBlock Listing Six Monthly Return
30th Jun 20207:00 amRNSIQGeo announces major contract expansion
29th Jun 202012:09 pmRNSDirectors' Dealings
15th Jun 20203:33 pmRNSResults of Annual General Meeting
8th Jun 20209:39 amRNSDirectors' Dealings
26th May 20207:00 amRNSDirectors' Dealings
21st May 20207:00 amRNSPosting of the Notice of Annual General Meeting
18th May 20203:29 pmRNSDirectors’ Dealings
13th May 20203:30 pmRNSDirector's Dealings
15th Apr 20209:27 amRNSDirector's Dealings
7th Apr 20207:00 amRNSPosting of Annual Financial Report
1st Apr 20204:18 pmRNSDirector's Dealings
30th Mar 20206:01 pmRNSDirector's Dealings
26th Mar 20207:00 amRNSTEPCO major contract expansion and COVID-19 update
24th Mar 20208:08 amRNSDirectors' Dealing
17th Mar 20204:26 pmRNSDirector's dealings
17th Mar 20204:21 pmRNSTR1 notification of major holdings
13th Mar 202010:55 amRNSDirectors' Dealings
11th Mar 20201:43 pmRNSDirector's Dealings
9th Mar 20207:00 amRNSAnnual Financial Report
3rd Feb 20202:59 pmRNSDirector's Dealing and Total Voting Rights
28th Jan 20207:00 amRNSTrading update
9th Jan 20204:30 pmRNSDirectors' dealings
2nd Jan 20205:16 pmRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.